Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.60 |
| ▸ | CASP1 | P29466 | 1/20 | 0.60 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | PGR | P06401 | 2/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9765753 | 0.95 | KDM4E (0.56) | KDM4EHSD17B10CASP1CACNA1CALDH1A1 | |
| SCHEMBL9765777 | 0.95 | KDM4E (0.59) | KDM4EHSD17B10CASP1CACNA1CALDH1A1 | |
| SCHEMBL7430107 | 0.91 | KDM4E (0.51) | KDM4EHSD17B10CASP1CACNA1CALDH1A1 | |
| SCHEMBL10555153 | 0.81 | KDM4E (0.64) | KDM4EHSD17B10CASP1CACNA1CALDH1A1 | |
| SCHEMBL11364576 | 0.80 | KDM4E (0.41) | KDM4EHSD17B10CASP1CACNA1CALDH1A1 | |
| SCHEMBL11356558 | 0.80 | KDM4E (0.41) | KDM4EHSD17B10CASP1CACNA1CALDH1A1 | |
| SCHEMBL9833019 | 0.80 | CACNA1C (0.64) | KDM4EHSD17B10CASP1CACNA1CALDH1A1 | |
| SCHEMBL9765762 | 0.79 | KDM4E (0.68) | KDM4EHSD17B10CASP1CACNA1CALDH1A1 | |
| SCHEMBL27676982 | 0.76 | KDM4E (0.58) | KDM4EHSD17B10CASP1CACNA1CALDH1A1 | |
| SCHEMBL9835820 | 0.76 | CA1 (0.64) | KDM4EHSD17B10CASP1CACNA1CALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2011060944-A2 | ACTIVE PHARMACEUTICAL INGREDIENT CAPSULES AND POLYUNSATURATED FATTY ACID ESTERS | GP PHARM, S.A. (ES) | 2011-05-26 | — | — | WO | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-0639986-A1 | TOPICAL OPHTHALMIC COMPOSITIONS COMPRISING A COMBINATION OF CALCIUM ANTAGONISTS WITH KNOWN ANTIGLAUCOMA AGENTS | ALCON LABORATORIES, INC. (US) | 1995-03-01 | — | — | EP | claimed |
| WO-1993023082-A1 | TOPICAL OPHTHALMIC COMPOSITIONS COMPRISING A COMBINATION OF CALCIUM ANTAGONISTS WITH KNOWN ANTIGLAUCOMA AGENTS | ALCON LABORATORIES, INC. (US) | 1993-11-25 | — | — | WO | claimed |
| EP-0301133-A2 | Long acting formulation | SYNTEX (U.S.A.) INC. (US) | 1989-02-01 | — | — | EP | claimed |
| EP-3485881-B1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | HARVARD COLLEGE (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20230241047-A1 | TREATMENT FOR DOPAMINERGIC DISORDERS | NORTHWESTERN UNIVERSITY | 2023-08-03 | — | — | US | disclosed |
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | US | disclosed |
| US-20220304994-A1 | TREATMENT FOR DOPAMINERGIC DISORDERS | NORTHWESTERN UNIVERSITY | 2022-09-29 | — | — | US | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| WO-1990010005-A1 | PYRIDYLCARBOXYL-ISOSORBIDE DERIVATIVE, MANUFACTURING PROCESS AND USES | HEINRICH MACK NACHF. (DE) | 1990-09-07 | — | — | WO | disclosed |
| EP-0385348-A1 | Pyridylcarboxyl-isosorbide derivative, manufacturing process and uses | Heinrich Mack Nachf. (DE) | 1990-09-05 | — | — | EP | disclosed |
| US-4940556-A | SUSTAINED RELEASE OF CALCIUM CHANNEL BLOCKERS | SYNTEX (U.S.A.) INC. (US) | 1990-07-10 | — | — | US | disclosed |
| US-4885305-A | ADMINISTERING NICARDIPINE OR ITS HYDROCHLORIDE SALT | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1989-12-05 | — | — | US | disclosed |
| EP-0301133-A2 | Long acting formulation | SYNTEX (U.S.A.) INC. (US) | 1989-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | OPRL1, MRGPRX1, RAMP1 | KDM4E 3030/4885HSD17B10 4639/4885CASP1 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.